Naxions Secures Tens of Millions in Series A+ Funding Led by IQVIA to Address Pharma Marketing Challenges with Big Data

VCBeat (WeChat ID: vcbeat) has learned that Naxions Co., Ltd. recently announced the completion of its tens-of-millions-yuan Series A+ financing round, with IQVIA (formerly QuintilesIMS) as the investor. The funds will be primarily used for talent acquisition, product development, and market expansion.

Currently, amid rising cost pressures, the continuous introduction of policies and regulations, ongoing reforms within healthcare institutions, and the increasing complexity of the overall healthcare market, the pharmaceutical industry is undergoing significant transformation and adjustment. Traditional business models, such as marketing strategies primarily reliant on high-frequency, face-to-face visits by medical representatives, are facing considerable challenges. Meanwhile, with the widespread adoption of digital marketing among pharmaceutical companies, there is a growing desire to leverage digital tools to expand more rapidly and efficiently into primary care and niche markets that are difficult to penetrate effectively through traditional methods, extending beyond core markets.

Naxions Co.,Ltd., established in 2015, has been deeply engaged in the pharmaceutical industry, focusing on providing digital marketing solutions for pharmaceutical companies. Its vision is:Enhancing the Marketing Efficiency of Pharmaceutical Companies Through Big Data Technologies.Naxions Co., Ltd. applies its integrated solution of “data acquisition + analysis/management tools/business consulting + execution” to pharmaceutical enterprises. By leveraging leading big data processing technologies and implementing more precise online marketing strategies, the company is committed to helping pharmaceutical companies transform traditional pharmaceutical marketing models and establish a more compliant and efficient digital marketing system.

Naxions Co., Ltd. starts with data collection and, through data cleaning, computation, and visualization, helps pharmaceutical companies gain a more scientific and larger-sample understanding of their target physicians’ and patients’ attitudes and behaviors toward their products. By leveraging these data, pharmaceutical companies can more precisely adjust their strategies, disseminate academic information, and enhance physicians’ professional expertise.

Ruan Wei, Founder and CEO of Naxions Co., Ltd., stated that the marketing pain points for pharmaceutical companies are highly evident. First, as tiered diagnosis and treatment deepen, the primary care market is becoming increasingly important for pharmaceutical firms. However, in this segment, companies face significant challenges in return on investment: soaring labor costs, stringent compliance requirements, and a fragmented customer base have led to currently low per-capita productivity, while scaling up the workforce is not easily feasible. Additionally, since first-generation digital marketing solutions were based on limited data and driven largely by experience, they targeted relatively broad audiences with weak correlations between marketing events. Consequently, leveraging new technologies to enhance the efficiency and precision of marketing activities remains a major challenge for many pharmaceutical companies.

Ruan Wei stated, “We need innovative approaches to address this issue and transform challenges into opportunities. Naxions Co., Ltd. has been committed to reconstructing fragmented data into authentic individual insights and perspectives, identifying leverage points through the ‘true’ voice of the market and contextualized user interpretations, thereby comprehensively enhancing commercial operational efficiency and improving the effectiveness of healthcare and pharmaceutical services. We refer to this as our Version 2.0 digital solution.”

This investment by IQVIA in Naxions Co., Ltd. is part of its strategic layout. As a global leader in information, technology, consulting, and research and development outsourcing, IQVIA has been committed to unlocking the value of data and combining it with consulting services to deliver actionable industry insights and solutions that span from strategy to tactics.

Mi Zihou, President of IQVIA North Asia, stated, “Innovation is the driving force behind the development of the healthcare industry. Only by leveraging innovative technologies and products to better listen to the voices of patients and healthcare professionals can we align with the national strategy for comprehensive health. This collaboration aims to create localized digital solutions, with the hope of further promoting the transformation and upgrading of the healthcare industry and advancing the practical implementation of Digital China.”

As can be seen, with technological advancements and data accumulation, the Version 2.0 digital solution leverages big data, AI, and data algorithms to provide objective and comprehensive insights for individual audiences. This enhances the personalization, systematicity, and foresight of academic communication, while safeguarding the security and privacy of data sources. The Version 2.0 solution helps pharmaceutical companies better understand the disease diagnosis and treatment perspectives of hospitals and physician groups, uncover unmet patient needs, and support enterprises in making evidence-based, trend-aware, and forward-looking business decisions, thereby building a new healthcare ecosystem that is “people-centric and value-driven.”

It is under this vision that the strategic partnership between Naxions and IQVIA was forged. Ruan Wei revealed that IQVIA has been present in China for over 20 years, and its real-time rolling statistics cover 85% of global pharmaceutical sales data, regarded as the gold standard for marketing reference in the pharmaceutical industry. Meanwhile, IQVIA possesses profound insights into the pharmaceutical sector, such as its accumulated knowledge across different disease areas, which can help Naxions accelerate its understanding of the industry and expedite the refinement of its products and platform.

Following this collaboration, the two parties will integrate online and offline medical data, combining and validating behavioral data of target groups with sales data to establish a 360-degree physician database. This initiative not only expands the breadth and depth of data but also extends data sources to the broader primary care market. Through cooperation with IQVIA, both parties will work together to help pharmaceutical companies gain more accurate insights into the real world, thereby maximizing the value of data.

In terms of competitors, Zephyr Health’s business model also involves providing data services to pharmaceutical companies. It obtains physicians’ prescribing patterns from data exchanges such as IMS Health and Symphony Health Solutions, and performs data processing and cleaning. Google Ventures has also participated in its funding.